Get started
Palvella Therapeutics, Inc.Palvella Therapeutics, Inc.Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

PVLA fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It is developing a pipeline of innovative treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded on December 13, 2024 and is headquartered in Wayne, PA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

PVLA does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company